Healthcare · Biotechnology
Price
$2.19
Market Cap
$609,891
Employees
2
Beta
0.67
Avg Volume
1,255,961
CEO
Allen Warren Davidoff
Business Description
XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to advancing and bringing to market medical treatments targeting a range of conditions, including chronic kidney ailments, diabetes, insulin resistance, metabolic syndrome, diabetic nephropathy, and various infections. Their pipeline includes XRx-008, a late-stage clinical program designed to address autosomal dominant polycystic kidney disease (ADPKD). Another key candidate is XRx-101, an agent aimed at reducing uric acid levels in COVID-19 patients, with the goal of mitigating acute kidney injury and related complications. Furthermore, they are developing XRx-221, a series of xanthine oxidase inhibitors intended for the management of diabetic nephropathy. XORTX also collaborates with the Icahn School of Medicine on research investigating acute kidney injury and hyperuricemia among hospitalized COVID-19 patients. The company's operations are headquartered in Vancouver, Canada.
Business History
Price Overview
Last updated: Jun 27, 2026 11:02am (just now)$2.19
+0.03 (+1.44%)
Day Range
$2.11 – $2.21
52-Week Range
$1.73 – $7.05
50-Day MA
$2.42
200-Day MA
$2.81
Volume
11,498.00
Share Structure
Outstanding
278,489.00
Float
250,023.00
Free Float
89.8%
High free float
— 89.8% of shares trade freely, ~10.2% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Small absolute float (0.3M shares) — even with a decent free float %, volume can be thin. Check average daily volume before sizing a position.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-0.15
Stock Price: $2.19
EPS (Diluted): -14.20
EPS (Diluted): -14.20
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
0.26
Stock Price: $2.19
Total Equity: $2.08M
Shares: 189,385
Total Equity: $2.08M
Shares: 189,385
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-0.12
Market Cap: $609,891
Total Debt: $37,219
Cash: $862,940
EBITDA: -$3.14M
Total Debt: $37,219
Cash: $862,940
EBITDA: -$3.14M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$-293,549
Market Cap: $609,891
Total Debt: $37,219
Cash: $862,940
Total Debt: $37,219
Cash: $862,940
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
0.00
Stock Price: $2.19
Revenue: $0.00
Shares: 189,385
Revenue: $0.00
Shares: 189,385
EV/Sales (Total value vs revenue — works when P/E can't)
API0.00
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
0.0%
Gross Profit: -$114,077
Revenue: $0.00
Revenue: $0.00
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
0.0%
Operating Income: -$3.31M
Revenue: $0.00
Revenue: $0.00
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
0.0%
Net Income: -$2.66M
Revenue: $0.00
Revenue: $0.00
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-135.3%
Net Income: -$2.66M
Total Equity: $2.08M
Total Equity: $2.08M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-238.9%
Operating Income: -$3.31M
Tax Rate: 0.0%
Equity: $2.08M
Total Debt: $37,219
Cash: $862,940
Tax Rate: 0.0%
Equity: $2.08M
Total Debt: $37,219
Cash: $862,940
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
1.61
Current Assets: $965,534
Current Liabilities: $597,980
Current Liabilities: $597,980
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.02
Short-Term Debt: $37,219
Long-Term Debt: $0.00
Total Debt: $37,219
Total Equity: $2.08M
Long-Term Debt: $0.00
Total Debt: $37,219
Total Equity: $2.08M
Rev/Share (Top-line per share)
Revenue / Shares Outstanding
—
Revenue: $0.00
Shares: 189,385
Shares: 189,385
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$10.99
Total Equity: $2.08M
Shares: 189,385
Shares: 189,385
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-14.88
Operating CF: -$2.82M
CapEx: $3.00
Shares: 189,385
CapEx: $3.00
Shares: 189,385
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $2.19
Stock Price: $2.19
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$2.66M
Net Income: -$2.66M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares XRTX against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 21, 2026 11:23pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | $18,017 | $74,605 | $141,958 | $111,642 | $114,077 |
| Gross Profit | $-18,017 | $-74,605 | $-141,958 | $-111,642 | $-114,077 |
| Operating Expenses | $2.9M | $12.4M | $4.8M | $3.8M | $3.2M |
| Operating Income | -$2.9M | -$12.4M | -$6.2M | -$3.9M | -$3.3M |
| Net Income | -$1.7M | -$7.0M | -$2.9M | -$3.2M | -$2.7M |
| EBITDA | -$2.9M | -$9.4M | -$6.0M | -$3.0M | -$3.1M |
| EPS | $-30.00 | $-118.00 | $-36.00 | $-27.45 | $-14.20 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 21, 2026 11:23pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $14.9M | $10.4M | $3.4M | $2.5M | $862,940 |
| Total Current Assets | $15.9M | $10.9M | $4.1M | $2.7M | $965,534 |
| Total Assets | $17.4M | $12.4M | $5.5M | $4.1M | $2.7M |
| Current Liabilities | $552,948 | $1.5M | $294,938 | $757,538 | $597,980 |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $4.2M | $5.4M | $825,938 | $757,538 | $597,980 |
| Total Equity | $13.2M | $7.0M | $4.6M | $3.3M | $2.1M |
| Retained Earnings | -$8.0M | -$15.7M | -$23.5M | -$21.2M | -$23.8M |
Cash Flow (Annual)
Last updated: Jun 21, 2026 11:23pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$4.8M | -$9.0M | -$6.6M | -$3.5M | -$2.8M |
| Capital Expenditure | $-31,807 | $-45,701 | $-46,363 | $-38,924 | $3 |
| Free Cash Flow | -$4.8M | -$9.0M | -$6.6M | -$3.5M | -$2.8M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $14.7M | -$4.4M | -$7.0M | $-974,016 | -$1.7M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 11:02am (just now)| Metric | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| Revenue |
$2.7M $2.7M – $2.7M
|
$128.8M $128.8M – $128.8M
|
$3.3M $3.3M – $3.3M
|
$16.0M $16.0M – $16.0M
|
| EBITDA | $0 | $0 | $0 | $0 |
| Net Income |
-$1.4M -$1.4M – -$1.4M
|
$-653,554 $-653,554 – $-653,554
|
$-331,425 $-331,425 – $-331,425
|
$757,544 $757,544 – $757,544
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 21, 2026 11:23pm (5d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | — | — |
| Gross Profit Growth | -314.1% | -90.3% | +21.4% | -2.2% |
| Operating Income Growth | -328.3% | +50.5% | +36.3% | +15.5% |
| Net Income Growth | -323.0% | +59.1% | -10.3% | +15.8% |
| EBITDA Growth | -224.2% | +36.1% | +49.4% | -3.3% |
Dividend History (Last 20)
Last updated: Jun 21, 2026 11:23pm (5d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2014-01-31 | $0.00 | 2014-01-13 | 2014-02-04 | 2014-02-17 |
| 2013-10-15 | $0.00 | 2013-10-03 | 2013-10-17 | 2013-11-01 |
| 2013-07-11 | $0.00 | 2013-07-01 | 2013-07-15 | 2013-07-30 |
| 2013-04-16 | $0.00 | 2013-04-04 | 2013-04-18 | 2013-05-02 |
| 2012-12-24 | $0.00 | 2012-12-18 | 2012-12-27 | 2012-12-31 |
| 2012-10-12 | $0.00 | 2012-10-02 | 2012-10-30 | |
| 2012-07-17 | $0.00 | 2012-07-05 | 2012-08-01 | |
| 2012-04-10 | $0.00 | 2012-03-29 | 2012-04-26 | |
| 2012-02-13 | $0.00 | 2012-02-01 | 2012-02-29 | |
| 2011-11-22 | $0.00 | 2011-11-14 | 2011-12-09 | |
| 2011-08-10 | $0.00 | 2011-08-01 | 2011-08-26 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for XRTX — it's generated by the pipeline (
market-narrative step).
No community reviews yet for XRTX.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30